vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and PagerDuty, Inc. (PD). Click either name above to swap in a different company.
PagerDuty, Inc. is the larger business by last-quarter revenue ($124.5M vs $94.9M, roughly 1.3× DYNAVAX TECHNOLOGIES CORP). PagerDuty, Inc. runs the higher net margin — 129.7% vs 28.4%, a 101.4% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs 4.7%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $24.1M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 5.9%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
PagerDuty, Inc. is an American cloud computing company specializing in a SaaS incident management platform for IT operations departments.
DVAX vs PD — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $124.5M |
| Net Profit | $26.9M | $161.6M |
| Gross Margin | — | 85.3% |
| Operating Margin | 22.4% | 6.5% |
| Net Margin | 28.4% | 129.7% |
| Revenue YoY | 17.7% | 4.7% |
| Net Profit YoY | 53.0% | 2827.7% |
| EPS (diluted) | $0.21 | $1.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $124.5M | ||
| Q3 25 | $94.9M | $123.4M | ||
| Q2 25 | $95.4M | $119.8M | ||
| Q1 25 | $68.2M | $121.4M | ||
| Q4 24 | $72.0M | $118.9M | ||
| Q3 24 | $80.6M | $115.9M | ||
| Q2 24 | $73.8M | $111.2M | ||
| Q1 24 | $50.8M | $111.1M |
| Q4 25 | — | $161.6M | ||
| Q3 25 | $26.9M | $9.6M | ||
| Q2 25 | $18.7M | $-7.2M | ||
| Q1 25 | $-96.1M | $-8.8M | ||
| Q4 24 | $7.0M | $-5.9M | ||
| Q3 24 | $17.6M | $-10.9M | ||
| Q2 24 | $11.4M | $-17.1M | ||
| Q1 24 | $-8.7M | $-28.2M |
| Q4 25 | — | 85.3% | ||
| Q3 25 | — | 84.6% | ||
| Q2 25 | — | 84.0% | ||
| Q1 25 | — | 83.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | — | 82.7% | ||
| Q2 24 | — | 82.6% | ||
| Q1 24 | — | 81.7% |
| Q4 25 | — | 6.5% | ||
| Q3 25 | 22.4% | 2.9% | ||
| Q2 25 | 15.1% | -8.6% | ||
| Q1 25 | -34.7% | -9.6% | ||
| Q4 24 | -2.3% | -8.7% | ||
| Q3 24 | 12.5% | -13.8% | ||
| Q2 24 | 7.0% | -19.5% | ||
| Q1 24 | -35.0% | -30.1% |
| Q4 25 | — | 129.7% | ||
| Q3 25 | 28.4% | 7.8% | ||
| Q2 25 | 19.6% | -6.0% | ||
| Q1 25 | -141.0% | -7.2% | ||
| Q4 24 | 9.8% | -5.0% | ||
| Q3 24 | 21.8% | -9.4% | ||
| Q2 24 | 15.4% | -15.4% | ||
| Q1 24 | -17.2% | -25.3% |
| Q4 25 | — | $1.69 | ||
| Q3 25 | $0.21 | $0.10 | ||
| Q2 25 | $0.14 | $-0.07 | ||
| Q1 25 | $-0.77 | $-0.12 | ||
| Q4 24 | $0.07 | $-0.07 | ||
| Q3 24 | $0.12 | $-0.14 | ||
| Q2 24 | $0.08 | $-0.26 | ||
| Q1 24 | $-0.07 | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $547.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $534.1M | $320.5M |
| Total Assets | $946.5M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $547.8M | ||
| Q3 25 | $160.2M | $567.9M | ||
| Q2 25 | $99.1M | $597.1M | ||
| Q1 25 | $51.7M | $570.8M | ||
| Q4 24 | $95.9M | $542.2M | ||
| Q3 24 | $119.3M | $599.3M | ||
| Q2 24 | $112.5M | $592.8M | ||
| Q1 24 | $132.0M | $571.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $484.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $489.5M |
| Q4 25 | — | $320.5M | ||
| Q3 25 | $534.1M | $180.7M | ||
| Q2 25 | $494.2M | $145.7M | ||
| Q1 25 | $530.9M | $129.8M | ||
| Q4 24 | $596.8M | $111.6M | ||
| Q3 24 | $681.4M | $164.7M | ||
| Q2 24 | $642.8M | $174.0M | ||
| Q1 24 | $618.5M | $171.6M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | $946.5M | $891.5M | ||
| Q2 25 | $918.4M | $926.8M | ||
| Q1 25 | $945.9M | $927.3M | ||
| Q4 24 | $986.3M | $866.8M | ||
| Q3 24 | $1.1B | $916.0M | ||
| Q2 24 | $1.0B | $924.0M | ||
| Q1 24 | $986.6M | $925.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.73× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 2.85× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $24.8M |
| Free Cash FlowOCF − Capex | $32.6M | $24.1M |
| FCF MarginFCF / Revenue | 34.4% | 19.3% |
| Capex IntensityCapex / Revenue | 1.3% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.26× | 0.15× |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $117.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $24.8M | ||
| Q3 25 | $33.8M | $34.0M | ||
| Q2 25 | $23.4M | $30.7M | ||
| Q1 25 | $-19.6M | $31.4M | ||
| Q4 24 | $53.0M | $22.1M | ||
| Q3 24 | $19.5M | $35.8M | ||
| Q2 24 | $10.7M | $28.6M | ||
| Q1 24 | $-16.7M | $22.2M |
| Q4 25 | — | $24.1M | ||
| Q3 25 | $32.6M | $33.1M | ||
| Q2 25 | $22.0M | $30.2M | ||
| Q1 25 | $-23.6M | $30.3M | ||
| Q4 24 | $49.5M | $21.5M | ||
| Q3 24 | $18.1M | $35.1M | ||
| Q2 24 | $9.9M | $28.2M | ||
| Q1 24 | $-17.4M | $21.2M |
| Q4 25 | — | 19.3% | ||
| Q3 25 | 34.4% | 26.8% | ||
| Q2 25 | 23.0% | 25.2% | ||
| Q1 25 | -34.6% | 24.9% | ||
| Q4 24 | 68.8% | 18.1% | ||
| Q3 24 | 22.5% | 30.3% | ||
| Q2 24 | 13.5% | 25.4% | ||
| Q1 24 | -34.3% | 19.1% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | 1.3% | 0.7% | ||
| Q2 25 | 1.5% | 0.4% | ||
| Q1 25 | 5.8% | 0.9% | ||
| Q4 24 | 4.8% | 0.5% | ||
| Q3 24 | 1.7% | 0.5% | ||
| Q2 24 | 1.1% | 0.4% | ||
| Q1 24 | 1.5% | 0.9% |
| Q4 25 | — | 0.15× | ||
| Q3 25 | 1.26× | 3.55× | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
PD
| US | $88.8M | 71% |
| Non Us | $35.7M | 29% |
